Navigation Links
Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation

SAN FRANCISCO, Jan. 5, 2012 /PRNewswire/ -- Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.

In preclinical studies, CTX-4430 has demonstrated the ability to safely and effectively reduce the progression of chronic inflammation in several animal models. LTA4H is a key enzyme in the production of the major pro-inflammatory mediator Leukotriene B4 (LTB4).  LTA4H and receptors to LTB4 are known to be elevated in a number of human lung diseases including Cystic Fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). Additionally, elevated levels of LTA4H recently have been located at active demyelinating lesions in the brains of patients with Multiple Sclerosis (MS). Thus, CTX-4430 has the potential to be a first-in-class oral treatment for multiple indications with unmet clinical need.

"The acquisition of CTX-4430 and the entire LTA4H project gives us several unique opportunities to introduce superior products to fulfill unmet medical needs" said Dr. Michael R. Hanley, Chief Executive Officer of Celtaxsys. "The addition of the LTA4H project to our development portfolio fits perfectly with our core business of modulating innate immunity to treat chronic inflammatory disorders, especially in our major areas of interest, Cystic Fibrosis and Multiple Sclerosis."

William Guilford, President of Estrellita, stated, "We are very pleased to conclude this transaction with Celtaxsys who will continue the development of CTX-4430. Celtaxsys' management has a proven track record of successfully developing value-added therapies for important indications, with particular strength in the field of inflammation and therefore is an ideal choice to move CTX-4430 through the clinic and onto the market."

About Celtaxsys

Celtaxsys is a privately held biotechnology company focused on the discovery, development, and commercialization of innovative pharmaceutical products for the treatment of inflammatory and autoimmune diseases. Celtaxsys was founded in 2005 as an early stage drug discovery company specializing in innate immune response and the Company's platform is designed to capture the synergy between three key scientific areas of discovery: Innate Immunity; The Neutrophil; and the treatment of Inflammatory Disease. Celtaxsys has offices in San Francisco, California and Atlanta, Georgia. For more information and corporate background, please visit

About Estrellita

Estrellita is a privately held San Francisco Bay Area company that acquired the rights to the small molecule LTA4H inhibitor, EP-501, from a major pharmaceutical company. The company, led by Dr. William Guilford, was developing the novel orally-available drug as a potential safe and effective treatment for a wide range of chronic inflammatory diseases.

Forward Looking Statements

Statements included in this press release that are not a description of historical facts may be forward looking statements.  The inclusion of forward looking statements should not be regarded as a representation by Celtaxsys that any of its plans will be achieved.  Actual results may differ materially from those anticipated or set forth in this press release due to the risks and uncertainties inherent in Celtaxsys's business including, without limitation, statements about difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products, unexpected performance or side effects of its products, the scope and validity of its products' patent protection, competition from other companies and its ability to obtain additional financing to support its operations.  All forward looking statements are qualified in their entirety by this statement and Celtaxsys undertakes no obligation to revise or update this press release to reflect events or circumstances occurring after the date hereof.




SOURCE Celtaxsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Michael Hanley Joins Celtaxsys as CEO
2. Dr. H. Daniel Perez Joins Celtaxsys Board of Directors
3. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
4. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
5. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
6. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
7. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. Circassia Acquires North American and Japanese Rights to Dopexamine
10. CPA Acquires Renowned German Patent Research Specialist, SVPG
11. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
Breaking Biology Technology:
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
Breaking Biology News(10 mins):